KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation (2018 - 2025)

Esperion Therapeutics' Share-based Compensation history spans 8 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 14.9% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $9.9 million, down 17.7%, while the annual FY2025 figure was $9.9 million, 17.7% down from the prior year.
  • Share-based Compensation reached $2.4 million in Q4 2025 per ESPR's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.6 million in Q2 2021 to a low of $2.3 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $3.7 million, with a median of $3.1 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 376.89% in 2021, then plummeted 58.91% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $4.5 million in 2021, then fell by 16.96% to $3.7 million in 2022, then decreased by 21.4% to $2.9 million in 2023, then dropped by 3.94% to $2.8 million in 2024, then fell by 14.9% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Share-based Compensation are $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025).